Showing results (851-860 of 934) with videos related to

Sort By:
Pageof 94
The Journal of Infectious Diseases|May 10, 2022
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) TrialHana M El Sahly, Lindsey R Baden, Brandon Essink, et al.
Neurology|May 3, 2019
"Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal studyMassimiliano Calabrese, Claudio Gasperini, Carla Tortorella, et al.
Antimicrobial Agents and Chemotherapy|September 25, 2004
A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic propertiesDavid B Olsen, Anne B Eldrup, Linda Bartholomew, et al.
Journal of Neurology|August 23, 2024
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimodAntonio Carotenuto, Cristina Di Monaco, Laura Papetti, et al.
European Heart Journal Open|June 12, 2026
Baseline characteristics of patients enrolled in the AZIMUTH trial: an e-health-integrated, smartphone app-based model of care for heart failure patientsDomenico D'Amario, Donato Antonio Paglianiti, Renzo Laborante, et al.
Aging Clinical and Experimental Research|April 26, 2005
The Caregiver Burden Inventory in evaluating the burden of caregivers of elderly demented patients: results from a multicenter studyMartina Marvardi, Paola Mattioli, Liana Spazzafumo, et al.
International Journal of Cardiology|August 29, 2020
Catheterization laboratory activity before and during COVID-19 spread: A comparative analysis in Piedmont, Italy, by the Italian Society of Interventional Cardiology (GISE)Giorgio Quadri, Andrea Rognoni, Enrico Cerrato, et al.
Journal of the Neurological Sciences|April 10, 2021
A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgiaD Ferraro, P Annovazzi, R Lanzillo, et al.
Science (New York, N.Y.)|October 13, 2018
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapyRazvan Cristescu, Robin Mogg, Mark Ayers, et al.
Nature Communications|August 29, 2024
Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phasesLindsey R Baden, Hana M El Sahly, Brandon Essink, et al.
Pageof 94